Minimal effects of dextroamphetamine on scopolamine-induced cognitive impairments in humans.
The central anticholinergic drug scopolamine has been used to model aspects of the memory impairment that occurs in Alzheimer's disease and in aging. To determine whether nonspecific stimulant effects can attenuate the cognitive impairment induced by scopolamine, we studied the effects of scopolamine and the stimulant dextroamphetamine in 17 young normal volunteers. After a baseline day of cognitive testing, subjects participated in two study days, in which they received dextroamphetamine (d-AMP) (0.25 mg/kg p.o.) + scopolamine (0.5 mg i.v.) and placebo + scopolamine, in randomized order under double-blind conditions. There were no statistically significant differences in cognitive test performance between the two drug conditions with the exception of one of the category retrieval tasks. Stimulant effects were documented to occur by other measures. We conclude that d-AMP at the dose used does not attenuate the memory impairment induced by scopolamine.
Martinez
R
R
Section on Geriatric Psychopharmacology, National Institute of Mental Health, Bethesda, Maryland, USA.
Molchan
S E
SE
Lawlor
B A
BA
Thompson
K
K
Martinson
H
H
Latham
G
G
Weingartner
H
H
Sunderland
T
T
D000328:Adult; D000544:Alzheimer Disease / Q000523:psychology; D001288:Attention / Q000187:drug effects; D000697:Central Nervous System Stimulants / Q000494:pharmacology*; D003071:Cognition / Q000187:drug effects*; D003913:Dextroamphetamine / Q000494:pharmacology*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D011930:Reaction Time / Q000187:drug effects; D012601:Scopolamine / Q000633:toxicity*
D000697:Central Nervous System Stimulants; D012601:Scopolamine; D003913:Dextroamphetamine